Key facts
- Notable investors include Heda Ventures, Cherami Investment Group, BVCF.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for GenEros
- ·The full record, as it builds
Funding rounds
No funding rounds for GenEros are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GenEros
Developer of therapeutics intended for the treatment of autoimmune diseases and cancer. The company offers molecular profiling for precision treatment, and leverages translational research collaborations, enabling immunology and oncology markets to access mechanism-driven, pathway-specific therapeutic solutions.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2018
- Website
- generosbio.com/
- Ownership
- Privately Held (backing)
GenEros doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GenEros shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GenEros in its N-PORT filings yet. We sweep new filings monthly.